Corticosteroid Management in Sudden Sensorineural Hearing Loss

First‑Line Systemic Therapy

• The American Academy of Otolaryngology–Head and Neck Surgery (AAO‑HNS) recommends oral prednisolone 1 mg/kg/day (maximum 60 mg/day) as a single daily dose for 7–14 days, followed by a gradual taper, initiated within 2 weeks of symptom onset【@1】. (Evidence: systematic reviews of randomized trials – high quality)

• AAO‑HNS endorses this regimen as the initial therapy based on systematic reviews of randomized clinical trials【@1】.

Timing of Initiation

• Treatment should begin within 14 days of symptom onset; benefits have been reported when therapy is started up to 6 weeks after onset【@2】【@3】.

Intratympanic Steroid Therapy (Initial or Contraindicated Systemic Steroids)

• When systemic corticosteroids are contraindicated (e.g., uncontrolled diabetes, severe hypertension, active peptic ulcer, active tuberculosis), bilateral intratympanic steroids should be offered as the initial treatment【@2】.

• Intratympanic options include dexamethasone 24 mg/mL or methylprednisolone 40 mg/mL【@2】.

• The injection technique: 0.4–0.8 mL is delivered into the middle‑ear space via an anteriosuperior myringotomy after topical anesthesia【@2】.

• After injection, the patient should keep the head in an otologic position for 15–30 minutes per side【@2】.

• Up to 4 injections per ear may be administered over a 2‑week period【@2】.

• Audiograms must be performed before each subsequent intratympanic injection to monitor response【@2】.

• Evidence‑based regimen: methylprednisolone 62.5 mg/mL, 5 injections over 12 days, achieved a 73.6 % improvement rate in patients who failed systemic steroids【@4】.

Rescue Therapy

• If hearing recovery is incomplete 2–6 weeks after the initial systemic steroid course, bilateral intratympanic steroids should be offered as rescue therapy【@1】【@2】.

• AAO‑HNS recommends this intratympanic rescue approach【@1】.

Monitoring and Follow‑up

• Baseline audiometry should be obtained within 14 days of symptom onset to confirm the diagnosis【@2】.

• Audiograms are required during treatment, performed before each intratympanic injection【@2】.

• A post‑treatment audiogram is obtained after completing the therapeutic course【@2】.

• Repeat audiometry at 6 months post‑treatment is advised regardless of perceived recovery【@2】【@5】.

Expected Recovery Timeline

* 54.5 % of patients who recover show improvement within 10 days of combined therapy【@4】.

* 78 % achieve their final hearing level by 1 month, and 97 % by 3 months after treatment onset【@4】【@6】.

• Auditory improvement may continue up to 3 months, with most gain occurring in the first 2 months【@5】.

• Only 0.6 % demonstrate any recovery beyond 6 months【@4】【@6】.

Prognostic Indicators

• Presence of vertigo at onset predicts a poorer prognosis【@1】.

• Minimal change in hearing during the first 2 weeks predicts unlikely significant recovery【@1】.

• Recovery of at least half of the hearing loss within the first 2 weeks predicts a better prognosis【@1】.

Adverse Effects and Safety

• Short‑term (10–14 days) systemic steroid therapy may cause hyperglycemia, weight gain, insomnia, hypertension, increased appetite, mood changes, and gastric irritation【@1】【@5】.

• The risk of hypothalamic‑pituitary‑adrenal axis suppression and Cushing‑type syndrome is minimal with a 10–14‑day course【@1】.

• Systemic steroids are low‑cost compared with intratympanic therapy【@1】.

• Intratympanic steroids have minimal systemic exposure【@1】.

• Local adverse events of intratympanic therapy include transient pain, tympanic‑membrane perforation, transient dizziness, and infection【@1】【@5】.

• Intratympanic therapy incurs higher cost and requires multiple clinic visits【@1】; persistent tympanic‑membrane perforation is rare【@5】.

Dose Considerations

• A 2024 systematic review found mixed evidence for high‑dose (>1 mg/kg/day) versus standard‑dose regimens, with overall low‑quality evidence; AAO‑HNS therefore recommends the standard dose of 1 mg/kg/day【@1】.

Rehabilitation and Counseling

• Counseling on hearing‑aid fitting, cochlear implantation, and other auditory rehabilitation should not be delayed, as postponement leads to auditory deprivation and poorer outcomes【@2】.

• Discussions of temporary hearing assistance measures should begin when hearing loss is first identified【@6】.

Management of Late‑Onset Sudden Sensorineural Hearing Loss in Ramsay Hunt Syndrome

Timing and Clinical Significance

• The onset of sudden sensorineural hearing loss (SSNHL) two weeks after completing antiviral and corticosteroid therapy for Ramsay Hunt syndrome should be regarded as a new, separate episode, requiring its own 14‑day therapeutic window. 1
• The optimal therapeutic window for treating SSNHL is within 14 days of symptom onset, with clinically meaningful benefits reported up to 6 weeks. 1

Initial Pharmacologic Therapy (within 14 days)

• Systemic corticosteroids are the first‑line treatment for late‑onset SSNHL: prednisone 1 mg/kg/day (max 60 mg) for 7–14 days with a gradual taper. [1][2]
• When systemic steroids are contraindicated, intratympanic corticosteroid injection (dexamethasone 24 mg/mL or methylprednisolone 40 mg/mL, 0.4–0.8 mL) may be used as initial therapy, with up to four injections over two weeks. 1

Audiologic Evaluation and Monitoring

• Confirm the diagnosis with pure‑tone audiometry performed within 14 days of hearing loss onset. 3
• Obtain a post‑treatment audiogram to document response. 1
• Schedule follow‑up audiometry at 6 months regardless of perceived recovery. 2

Prognostic Indicators

• Recovery of at least 50 % of the hearing loss during the first two weeks predicts a favorable long‑term outcome. 4
• Minimal change in audiometric thresholds during the first two weeks predicts a low likelihood of significant recovery. 4
• Presence of vertigo at onset is associated with a poorer prognosis. [4][2]

Rescue Therapy for Incomplete Recovery (2–6 weeks)

• If hearing does not fully recover after the initial course, intratemporal corticosteroid rescue (typically 4–6 dexamethasone injections over two weeks) is recommended. 2
• A regimen of methylprednisolone 62.5 mg/mL given in five injections over 12 days has shown a 73.6 % improvement rate in patients who failed systemic steroids. (Evidence level not specified)
• Adjunctive hyperbaric oxygen therapy combined with steroids may be considered within one month of symptom onset, but it is not a strong recommendation. 2

Common Pitfalls to Avoid

• Do not assume that prior antiviral/corticosteroid treatment covers the new hearing loss; treat it as a distinct SSNHL episode. [2][1]
• Do not delay treatment—each day beyond the 14‑day window reduces efficacy. 1
• Do not rely solely on patient‑reported symptoms; objective audiometry is essential for diagnosis and monitoring. 3
• Routine additional antiviral therapy for late‑onset SSNHL is not recommended. [2][3]

Additional Diagnostic Work‑up

• Evaluate for retrocochlear pathology with magnetic resonance imaging or brainstem auditory evoked responses when indicated. 3

Rehabilitation and Counseling

• Discuss early audiologic rehabilitation options (hearing aids, cochlear implantation) to prevent auditory deprivation and improve outcomes. 2

Intratympanic Steroid Therapy for Sudden Sensorineural Hearing Loss

Indications & Timing

• The American Academy of Otolaryngology–Head and Neck Surgery (AAO‑HNS) recommends offering intratympanic steroids as salvage therapy when hearing recovery remains incomplete 2–6 weeks after initial systemic steroid treatment, using dexamethasone 5 mg/mL or methylprednisolone 40–62.5 mg/mL in 4–6 injections over 2 weeks. [5][6] (Guideline Level B)
• When systemic steroids are contraindicated (e.g., uncontrolled diabetes, severe hypertension, active peptic ulcer, active tuberculosis, glaucoma, myasthenia gravis, cataract, prior psychiatric reaction), intratympanic steroids may be used as initial therapy. [7][8]

Drug Selection & Dosing

• Dexamethasone 5 mg/mL is the most common agent, administered 0.4–0.8 mL per injection. 6
• Methylprednisolone 40 mg/mL is an alternative, also given 0.4–0.8 mL per injection. 7
• A higher‑concentration methylprednisolone 62.5 mg/mL protocol (5 injections over 12 days) achieved 73.6 % improvement in patients who failed systemic steroids. 7 (Level A – RCT)
• All five randomized controlled trials demonstrating efficacy used either dexamethasone or methylprednisolone, supporting both agents as effective. 6

Treatment Protocols

• Salvage therapy: Initiate 2–6 weeks after systemic steroids; deliver 4–6 injections (typically twice weekly) over 2 weeks. [5][6]
• Evidence timing: Four of five RCTs started intratympanic steroids within 7 days of completing systemic therapy, suggesting early salvage may be advantageous. 6
• Initial‑therapy protocol (when systemic steroids contraindicated): Up to 4 injections per ear over 2 weeks. [7][8]

Injection Technique

• The transtympanic needle perforation method is the standard delivery technique. [7][6]

Monitoring & Success Criteria

• Baseline audiometry should be obtained within 14 days of symptom onset to confirm diagnosis. 5
• Improvement definition: ≥10 dB decrease in pure‑tone average or ≥10 % increase in word‑recognition score. 6
• Expected outcomes: 37.5–47.6 % of patients achieve ≥10 dB improvement with salvage intratympanic therapy. 6

Contraindications & Risks

• Absolute contraindications: Active middle‑ear infection and pre‑existing tympanic‑membrane perforation. 7
• Relative risk: Perforation risk rises 17.5‑fold with a fifth or later injection. 7
• Most perforations resolve spontaneously or with a paper‑patch myringoplasty. [7][8]

Adverse Effects

• Transient injection‑site pain and brief caloric vertigo/dizziness are the most common, usually self‑limited. 8

Prognostic Factors

• Poor prognostic indicator: Minimal hearing change during the first 2 weeks predicts unlikely significant recovery. 5
• Vertigo at onset predicts a poorer overall prognosis, although it may indicate a better response to salvage intratympanic therapy. 5

Clinical Algorithm (AAO‑HNS)

• If hearing fully recovered → routine follow‑up.
• If recovery incomplete → proceed to salvage intratympanic therapy. [5][6]

Practical Considerations

• Intratympanic therapy incurs higher costs than systemic steroids due to multiple clinic visits and procedural fees. [5][8]

All bullet points are based on cited evidence from the American Academy of Otolaryngology–Head and Neck Surgery guidelines and associated randomized controlled trials.